Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.47 |
| ▸ | MEN1 | O00255 | 11/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924127 | 0.88 | MAPT (0.52) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1925224 | 0.87 | SMN1; SMN2 (0.44) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1924529 | 0.84 | MEN1 (0.60) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1923968 | 0.83 | BRAF (0.49) | MAPTLMNATP53TRPV1 | |
| SCHEMBL1924068 | 0.82 | MAPT (0.45) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL1924479 | 0.82 | MAPT (0.55) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1924524 | 0.81 | KDM4E (0.45) | MAPTKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL1925485 | 0.81 | MEN1 (0.43) | MAPTKMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL1924547 | 0.81 | ROCK2 (0.48) | MAPTKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL1923925 | 0.80 | MAPT (0.50) | MAPTKMT2AMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856043-B1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2011-06-08 | — | — | EP | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | claimed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | WEE1, WEE2, FARS2 | MAPT 1988/4885KMT2A 1844/4885MEN1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.